Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 607
- Registration Number
- NCT03369223
- Locations
- 🇦🇺
Local Institution - 0025, Frankston, Victoria, Australia
🇨🇦Local Institution - 0056, Ottawa, Ontario, Canada
🇮🇹Local Institution - 0020, Napoli, Italy
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 10
- Registration Number
- NCT03367715
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Brown University
- Target Recruit Count
- 46
- Registration Number
- NCT03355976
- Locations
- 🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸Women & Infants Hospital, Providence, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 11
- Registration Number
- NCT03347123
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 218
- Registration Number
- NCT03340129
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03333616
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Nivolumab with and Without Ipilimumab and Radiation Therapy in Treating Patients with Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03307616
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
- Conditions
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 6
- Registration Number
- NCT03305445
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 74
- Registration Number
- NCT03297593
- Locations
- 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭Spital Thurgau, Frauenfeld, Switzerland
🇨🇭Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland
Adoptive Cell Therapy Across Cancer Diagnoses
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 25
- Registration Number
- NCT03296137
- Locations
- 🇩🇰
Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.